N-(6-(4-(5-Amino-1,3,4-Thiadiazol-2-Yl)Butyl)Pyridazin-3-Yl)-2-(3-(Trifluoromethoxy)Phenyl)Acetamide manufacturers
- Glutaminase-IN-3
-
- $57.00
-
2026-07-15
- CAS:1439399-45-7
- Purity: 98.51%
- Supply Ability: 10g
|
| | N-(6-(4-(5-Amino-1,3,4-Thiadiazol-2-Yl)Butyl)Pyridazin-3-Yl)-2-(3-(Trifluoromethoxy)Phenyl)Acetamide Basic information |
| Product Name: | N-(6-(4-(5-Amino-1,3,4-Thiadiazol-2-Yl)Butyl)Pyridazin-3-Yl)-2-(3-(Trifluoromethoxy)Phenyl)Acetamide | | Synonyms: | N-(6-(4-(5-Amino-1,3,4-Thiadiazol-2-Yl)Butyl)Pyridazin-3-Yl)-2-(3-(Trifluoromethoxy)Phenyl)Acetamide;N-(6-(4-(5-amino-1,3,4-thiadiazol-2-yl)butyl)pyridazin-3-yl)-2-(3-(trifluoromethoxy)phenyl)acetamide(WXC05490);N-[6-[4-(5-Amino-1,3,4-thiadiazol-2-yl)butyl]-3-pyridazinyl]-3-(trifluoromethoxy)benzeneacetamide;Glutaminase-IN-3;GlutaminaseIN3,Glutaminase IN 3;Benzeneacetamide, N-[6-[4-(5-amino-1,3,4-thiadiazol-2-yl)butyl]-3-pyridazinyl]-3-(trifluoromethoxy)-;Glutaminase-IN-3, 10 mM in DMSO | | CAS: | 1439399-45-7 | | MF: | C19H19F3N6O2S | | MW: | 452.45 | | EINECS: | | | Product Categories: | | | Mol File: | 1439399-45-7.mol |  |
| | N-(6-(4-(5-Amino-1,3,4-Thiadiazol-2-Yl)Butyl)Pyridazin-3-Yl)-2-(3-(Trifluoromethoxy)Phenyl)Acetamide Chemical Properties |
| density | 1.437±0.06 g/cm3(Predicted) | | storage temp. | 4°C, protect from light | | solubility | DMSO : 50 mg/mL (110.51 mM; Need ultrasonic) | | form | Solid | | pka | 11.93±0.70(Predicted) | | color | Light yellow to yellow |
| | N-(6-(4-(5-Amino-1,3,4-Thiadiazol-2-Yl)Butyl)Pyridazin-3-Yl)-2-(3-(Trifluoromethoxy)Phenyl)Acetamide Usage And Synthesis |
| Uses | Glutaminase-IN-3 (compound 657) is a potent glutaminase inhibitor with an IC50 of 0.24 μM for Glutaminase 1 (GLS1). Glutaminase-IN-3 is extracted from patent WO2014089048A1, compound 657[1]. | | Biological Activity | Glutaminase-IN-3 (compound 657) is a potent glutaminase inhibitor with an IC50 of 0.24 μM for Glutaminase 1 (GLS1). Glutaminase-IN-3 is extracted from patent WO2014089048A1, compound 657[1]. | | References | [1]. Mark K. Bennett, et al. Treatment of cancer with heterocyclic inhibitors of glutaminase. WO2014089048A1. |
| | N-(6-(4-(5-Amino-1,3,4-Thiadiazol-2-Yl)Butyl)Pyridazin-3-Yl)-2-(3-(Trifluoromethoxy)Phenyl)Acetamide Preparation Products And Raw materials |
|